Live price temporarily unavailable.
MiNK Therapeutics (INKT) is a Health Care company. Latest news and coverage below.
| FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Operating income | −$14.6M | −$28.4M | −$30.9M | −$22.9M | −$11.3M | −$12.6M |
| Net income | −$16.2M | −$30.2M | −$28.0M | −$22.5M | −$10.8M | −$12.5M |
| EPS (diluted) | −$67.00 | −$11.60 | −$8.30 | −$6.54 | −$2.86 | −$2.93 |
| Balance sheet | ||||||
| Cash and equivalents | $2.69M | $38.9M | $19.6M | $3.37M | $4.58M | $13.4M |
| Total assets | $4.56M | $40.2M | $21.5M | $4.55M | $5.72M | $14.2M |
| Total liabilities | $58.4M | $16.5M | $21.9M | $22.6M | $25.3M | $28.5M |
| Shareholders' equity | −$53.9M | $23.8M | −$401.3K | −$18.1M | −$19.6M | −$14.2M |
| Cash flow | ||||||
| Operating cash flow | −$8.34M | −$12.8M | −$18.9M | −$15.8M | −$9.56M | −$5.93M |
| Capital expenditure | $95.2K | $249.0K | $250.0K | $73.6K | — | — |
| Free cash flow | −$8.43M | −$13.1M | −$19.1M | −$15.8M | — | — |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | −$1.88M | −$2.50M | −$2.70M | −$4.05M | −$3.18M | −$2.71M | −$2.88M | −$3.22M |
| Net income | −$1.81M | −$2.46M | −$2.77M | −$4.24M | −$2.89M | −$2.60M | −$2.74M | −$3.13M |
| EPS (diluted) | −$0.46 | −$0.57 | −$0.70 | −$1.06 | −$0.65 | −$0.52 | −$0.57 | −$0.62 |
| Balance sheet | ||||||||
| Cash and equivalents | $6.33M | $4.58M | $3.23M | $1.68M | $9.50M | $13.4M | $9.53M | $8.81M |
| Total assets | $7.37M | $5.72M | $4.27M | $2.48M | $15.0M | $14.2M | $10.4M | $9.62M |
| Total liabilities | $24.9M | $25.3M | $26.1M | $27.7M | $28.5M | $28.5M | $23.1M | $23.6M |
| Shareholders' equity | −$17.6M | −$19.6M | −$21.8M | −$25.2M | −$13.5M | −$14.2M | −$12.7M | −$14.0M |
| Cash flow | ||||||||
| Operating cash flow | −$2.99M | −$1.73M | −$1.34M | −$1.57M | −$941.3K | −$2.07M | −$1.73M | −$2.08M |
From MiNK Therapeutics's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning MiNK Therapeutics in our feed yet.